You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bcma

Showing 26 - 50 of 261
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Multiple Myeloma Trial in Hangzhou, Wuhan (CART-BCMA)

Recruiting
  • Multiple Myeloma
  • Hangzhou, China
  • +1 more
Apr 23, 2022

Relapsed/Refractory Multiple Myeloma Trial in Beijing, Hangzhou, Shanghai (LCAR-BCDR cells product)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LCAR-BCDR cells product
  • Beijing, Beijing, China
  • +3 more
Dec 15, 2022

Multiple Myeloma Trial in New York (EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.)

Active, not recruiting
  • Multiple Myeloma
  • EGFRt/BCMA-41BBz CAR T cell
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Relapsed/Refractory Multiple Myeloma Trial in Xi'an (LUCAR-B68 cells product)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LUCAR-B68 cells product
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Aug 10, 2022

Relapsed/Refractory Multiple Myeloma Trial in New York, Nashville, Salt Lake City (CB-011)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • CB-011
  • New York, New York
  • +3 more
Feb 15, 2023

POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia Trial in Hangzhou (CD19/BCMA CAR T-cells)

Recruiting
  • POEMS Syndrome
  • +3 more
  • CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 21, 2022

Multiple Myeloma Trial in United States (SEA-BCMA, dexamethasone, pomalidomide)

Recruiting
  • Multiple Myeloma
  • Palo Alto, California
  • +10 more
Aug 24, 2022

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023

CS1+ or BCMA+ Multiple Myeloma Trial in Wuhan (Conditioning chemo followed by CAR T cell infusion)

Recruiting
  • CS1+ or BCMA+ Multiple Myeloma
  • Conditioning chemotherapy followed by CAR T cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Feb 11, 2022

Multiple Myeloma Trial (Teclistamab, Tocilizumab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jul 24, 2023

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

CAR-T Trial in Hangzhou (GC012F injection)

Recruiting
  • CAR-T
  • GC012F injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • APRIL CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
May 3, 2022

Multiple Myeloma Trial in Chicago, Boston, Milwaukee (PHE885)

Recruiting
  • Multiple Myeloma
  • PHE885
  • Chicago, Illinois
  • +4 more
Jul 28, 2022

Multiple Myeloma Trial in Beijing, Suzhou (CAR-BCMA T Cells)

Recruiting
  • Multiple Myeloma
  • CAR-BCMA T Cells
  • Beijing, Beijing, China
  • +1 more
Jan 26, 2023

Multiple Myeloma, Refractory Trial in Chongqing (Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan)

Recruiting
  • Multiple Myeloma, Refractory
  • Anti-BCMA CAR-NK Cells
  • +2 more
  • Chongqing, Chongqing, China
    Department of Hematology, Xinqiao Hospital
Nov 21, 2021

Multiple Myeloma Trial (Linvoseltamab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 12, 2023

Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)

Not yet recruiting
  • Multiple Myeloma
  • Allogeneic Stem Cell Transplantation
  • CARTemis-1
  • Santander, Cantabria, Spain
  • +4 more
Aug 1, 2023

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Mar 23, 2022

Scleroderma, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Scleroderma
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Sjogren's Syndrome, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Sjogren's Syndrome
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Extramedullary Multiple Myeloma Trial in Wuhan (Selinexor, CT103A)

Recruiting
  • Extramedullary Multiple Myeloma
  • Wuhan, Hu Bei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022

Immune Nephritis, Autoimmune Diseases, Lupus Nephritis Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Immune Nephritis
  • +2 more
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Multiple Myeloma Trial in Shanghai (GC012F injection)

Unknown status
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 21, 2021